TrialClinical and translational science2023

A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects.

Hongjie Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.